Sabizabulin (VERU-111)
Slow progression or promote regression of atherosclerosis in patients with atherosclerotic coronary artery disease (CAD)
Phase 2Planned
Key Facts
Indication
Slow progression or promote regression of atherosclerosis in patients with atherosclerotic coronary artery disease (CAD)
Phase
Phase 2
Status
Planned
Company
About Veru
Veru Inc. is a biopharmaceutical company targeting significant unmet needs in cardiometabolic and inflammatory diseases with its two lead clinical candidates. The company is strategically positioning enobosarm as a combination therapy to address the muscle-wasting side effect of popular GLP-1 receptor agonists for weight loss, aiming to improve the quality of weight reduction. Concurrently, it is developing sabizabulin to target the inflammatory drivers of atherosclerosis. Veru operates as a public company and is led by a management team with extensive experience in drug development and commercialization.
View full company profile